ALGERNON PHRMCTCLS A INC - AGNPF STOCK NEWS

Welcome to our dedicated page for ALGERNON PHRMCTCLS A news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on ALGERNON PHRMCTCLS A stock.

Algernon Pharmaceuticals Inc. (symbol: AGNPF) is a Canadian clinical stage pharmaceutical development company dedicated to advancing treatments for unmet global medical needs. The company operates multiple research programs targeting chronic kidney disease, chronic cough, and non-alcoholic steatohepatitis (NASH). Algernon is also the parent company of Algernon NeuroScience, a subsidiary focused on the investigation of a proprietary form of psychedelic DMT for stroke and traumatic brain injury.

Recently, Algernon has achieved significant milestones, such as receiving a notice of intention to grant a patent from the Chinese Patent Office for its antifibrotic drug candidate NP-251 (Repirinast). This patent, which will be valid through 2038, enhances the global protection of the company's intellectual property. Another notable development includes the sale of its NP-120 (Ifenprodil) research program to Seyltx Inc. for USD $2 million and a 20% equity stake in Seyltx. Ifenprodil targets chronic cough by inhibiting NMDA receptors, and Seyltx is set to advance it through a Phase 2b clinical trial.

Algernon is also making strides with its DMT stroke research program under Algernon NeuroScience. The company plans to proceed with a Phase 2a study investigating the neuroplasticity effects of DMT in stroke patients. This program represents a pioneering effort to explore the potential of psychedelics in promoting brain recovery post-stroke.

Financially, Algernon has secured multiple patents in various markets, including Japan, Canada, Europe, and the United States, for its lead candidates. The company's forward-looking strategy involves robust intellectual property protection, strategic partnerships, and focused clinical trials.

In addition to its clinical advancements, Algernon has engaged ICP Securities Inc. for automated market making services to enhance liquidity and market presence. The company actively communicates with investors and stakeholders, as evidenced by planned special CEO interviews and Q&A sessions.

Algernon Pharmaceuticals is committed to developing effective treatments through rigorous research and strategic collaborations, positioning itself as a leader in innovative pharmaceutical solutions.

12/27/2023 04:01 PM

News

Algernon Pharmaceuticals Announces Closing of Private Placement

Rhea-AI Summary

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) closes non-brokered private placement, raising $280,000 for working capital.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

26%

Tags

12/27/2023 07:00 AM

News

Algernon Pharmaceuticals Announces Increase to Private Placement

Rhea-AI Summary

Algernon Pharmaceuticals Inc. (AGN) announces an increase to its non-brokered private placement, from gross proceeds of $150,000 to $280,000, with each Unit consisting of one Common Share and one Common Share purchase warrant. The Offering is expected to close on December 27, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/12/2023 07:42 PM

News

Algernon Pharmaceuticals Announces Private Placement

Rhea-AI Summary

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) announces a non-brokered private placement for gross proceeds of $150,000 through the issuance of units at an issue price of $0.075 per Unit. Each Unit consists of one Class A common share and one Common Share purchase warrant. The Offering is expected to close on December 20, 2023, and the Company will use the proceeds for working capital purposes.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.46%

Tags

11/30/2023 07:00 AM

News

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

Rhea-AI Summary

Algernon Pharmaceuticals Inc. (AGN) receives a notice of intention to grant from the Chinese Patent Office for patent application No. 112654357, entitled 'Compositions and Methods for Treating Non-Alcoholic Steatohepatitis' with NP-251 (Repirinast). The patent will be valid through 2038, with additional protection possibilities. Repirinast has shown promising results in reducing hepatic fibrosis and NAFLD score in NASH models, positioning it as a strong candidate for both NASH and CKD indications. The company is strategically protecting its compounds through a comprehensive global intellectual property strategy.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

12.32%

Tags

11/22/2023 07:00 AM

News

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Rhea-AI Summary

Algernon Pharmaceuticals Inc. (AGN) has signed a Letter of Intent with Seyltx Inc. to acquire Algernon’s NP-120 research program for USD $2M cash and a 20% common share equity position in Seyltx. The transaction is subject to certain conditions including Seyltx financing and the negotiation and execution of a definitive agreement, expected within the next 90 days. Algernon's Phase 2a study of idiopathic pulmonary fibrosis and chronic cough showed a significant reduction in cough count, leading to the decision to advance to a Phase 2b cough study.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

34.47%

Tags

11/08/2023 07:00 AM

News

Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast

Rhea-AI Summary

Algernon Pharmaceuticals Inc. (AGN) Receives Japanese Patent for Repirinast to Treat NASH, CKD, and NAFLD, Valid Through 2038. The company's lead candidate shows promising results in reducing fibrosis and is a strong candidate for both indications.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-8.27%

Tags

09/06/2023 07:00 AM

News

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

Rhea-AI Summary

Algernon Pharmaceuticals receives patent for CKD program drug NP-251 (Repirinast), positive data from NASH model, global IP suite expands

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.4%

Tags

08/08/2023 07:00 AM

News

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Rhea-AI Summary

Algernon Pharmaceuticals Inc. announces completion of feasibility study and finalization of clinical trial design for Phase 2 DMT Stroke study. The study will investigate the use of DMT for the treatment of stroke and its ability to promote neuroplasticity in brain injuries. The decision to investigate DMT for stroke treatment was based on a ground-breaking rat occlusion stroke study that showed DMT reduced infarct volume and led to full recovery of motor function. The Phase 2 study will focus on safety and measures of efficacy including preservation of brain tissue, motor recovery, depression, and biomarkers linked to stroke pathophysiology.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-7.67%

Tags

07/14/2023 06:00 PM

News

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

Rhea-AI Summary

Algernon Pharmaceuticals announces non-brokered private placement for gross proceeds of CDN$205,000. Each unit consists of one common share and one common share purchase warrant. The offering is expected to close on July 21, 2023. The company will use the proceeds for working capital purposes.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/27/2023 07:00 AM

News

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.21%

Tags

FAQ

What is the current stock price of ALGERNON PHRMCTCLS A (AGNPF)?

The current stock price of ALGERNON PHRMCTCLS A (AGNPF) is $0.057 as of November 22, 2024.

What is the market cap of ALGERNON PHRMCTCLS A (AGNPF)?

The market cap of ALGERNON PHRMCTCLS A (AGNPF) is approximately 1.6M.

What is Algernon Pharmaceuticals Inc.'s main focus?

Algernon Pharmaceuticals Inc. focuses on developing treatments for chronic kidney disease, chronic cough, and investigating DMT for stroke and traumatic brain injury.

What recent achievements has Algernon Pharmaceuticals Inc. made?

Algernon recently received a notice of intention to grant a patent for NP-251 in China and sold its Ifenprodil program to Seyltx Inc. for $2 million and a 20% equity stake.

What is the significance of Repirinast for Algernon Pharmaceuticals?

Repirinast is Algernon's lead candidate for treating chronic kidney disease, showing significant reduction in fibrosis and benefiting from patents in multiple countries.

How is Algernon advancing its DMT stroke research program?

Algernon plans to conduct a Phase 2a study to investigate the effects of DMT on neuroplasticity in stroke patients, aiming to promote brain recovery.

What partnerships does Algernon Pharmaceuticals Inc. have?

Algernon has partnered with companies like Seyltx Inc. and ICP Securities Inc. for various strategic initiatives, including the sale of research programs and market making services.

What are the key areas of research for Algernon NeuroScience?

Algernon NeuroScience is focused on investigating psychedelic DMT for stroke and traumatic brain injury, particularly its potential to promote neuroplasticity.

What financial strategies does Algernon Pharmaceuticals pursue?

Algernon secures patents globally for its lead candidates, engages in strategic partnerships, and ensures liquidity through services like those provided by ICP Securities Inc.

What is Ifenprodil and its potential impact?

Ifenprodil is an NMDA receptor antagonist targeting chronic cough. It has shown promising results in reducing cough counts, especially in difficult-to-treat populations.

How does Algernon Pharmaceuticals engage with its investors?

Algernon actively communicates with its investors through CEO interviews, Q&A sessions, and regular updates on clinical advancements and strategic developments.

What is the significance of Algernon's recent market making agreement?

The agreement with ICP Securities Inc. aims to enhance the liquidity and market presence of Algernon's shares, correcting temporary imbalances in supply and demand.